Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1 Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes
Some trials even showed lower rates of depressive symptoms in GLP-1 groups, likely due to improved quality of life and reduced inflammation
Standard practice involves rotating injection sites among convenient locations (abdomen, thighs, upper arms) to prevent tissue damage while achieving systemic distribution
Minor side effects are rare and usually mild, often related to initial detoxification, such as mild gastrointestinal discomfort
Secondly, Trulicity slows down the emptying of the stomach, which helps to prolong feelings of fullness and increase satiety